A carregar...
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even with the current gold-standard first-line treatment—maximal safe resection and combination of radiotherapy with temozolomide chemotherapy—the median overall survival time is only approximately 15–17 months, becau...
Na minha lista:
| Publicado no: | Nat Rev Neurol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4782584/ https://ncbi.nlm.nih.gov/pubmed/26260659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrneurol.2015.139 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|